Effect of a Dietary Supplement on Weight Loss and Psychological Wellbeing in Overweight Individuals

Sponsor
Universidad Católica San Antonio de Murcia (Other)
Overall Status
Recruiting
CT.gov ID
NCT05758363
Collaborator
(none)
60
1
2
7.8
7.7

Study Details

Study Description

Brief Summary

The aim of this randomized, parallel, two-arm, placebo-controlled, double-blind, multicenter clinical trial is to evaluate the efficacy of a dietary supplement on weight loss and psychological well-being in overweight individuals.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Consumption of dietary supplement.
  • Other: Consumption of control product
N/A

Detailed Description

The duration of the study will be 6 months during which the investigational product or placebo will be consumed according to the assignment.

Subjects will be randomized to each of the study arms (consumption of the experimental product or control product).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Randomized Clinical Trial to Evaluate the Efficacy of a Dietary Supplement on Weight Loss and Psychological Wellbeing in Overweight Individuals
Actual Study Start Date :
Mar 9, 2023
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Nov 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental Group

Consumption of dietary supplement capsules for 6 months.

Dietary Supplement: Consumption of dietary supplement.
Consumption of a dietary supplement rich in glutathione, selenium, zinc, vitamin D and EPA/DHA. 1 capsule per day of the dietary supplement with breakfast.

Placebo Comparator: Control Group

Identically appearing placebo capsules consumed for 6 months.

Other: Consumption of control product
Consumption of 1 capsule per day of control product of identical appearance with breakfast.

Outcome Measures

Primary Outcome Measures

  1. Evaluation of weight loss [From baseline to 6 months later]

    Evaluation of weight loss by assessment of anthropometric measurements - Waist/hip ratio - Waist/height ratio.

Secondary Outcome Measures

  1. Quality of life by WHOQOL-BREF [From baseline to 6 months later]

    World Health Organization Quality of Life Brief version test. The raw scores are transformed into a normalized scale ranging from 4 to 20 and from 0 to 100. Higher scores indicating better quality of life.

  2. Quality of life by SF-36 [From baseline to 6 months later]

    Short Form 36 Health Survey Questionnaire (SF-36). The SF-36 contains 36 items that measure eight dimensions or scales. The scores for each dimension will be calculated in both raw and transformed form as indicated in the manual, with higher scores indicating better health status for that particular dimension.

  3. Depression [From baseline to 6 months later]

    Beck Depression Inventory test. The score ranges from 0 to 63, where the higher the score, the greater the signs of depression.

  4. Stress [From baseline to 6 months later]

    Perceived Stress Scale (PSS). Total scores range from 0 to 56 (higher scores indicate higher levels of stress).

  5. Anxiety [From baseline to 6 months later]

    State-Trait Anxiety Inventory (STAI) Test. Scores can vary between 0 to a maximum of 60. Higher scores correlate positively with higher levels of anxiety.

  6. Dietary intake [From baseline to 6 months later]

    Registration and subsequent nutritional evaluation with 3-day food frequency questionnaire (FFQ).

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adults (age: 30 - 70 YO)

  • BMI over 25 kg/m2.

  • Subjects who are smokers or non-smokers, but in any case who do not modify their nicotinic habits during their participation in the study.

Exclusion Criteria:
  • Subjects with eating disorders.

  • BMI less than 25 Kg/m2.

  • History of allergic hypersensitivity or poor tolerance to any component of the products under study.

  • Participation in another clinical trial in the three months prior to the study.

  • Unwillingness or inability to comply with clinical trial procedures.

  • Pregnant woman.

  • Participants with an active daily exercise activity.

  • Subjects whose condition makes them ineligible for the study at the investigator's discretion.

Contacts and Locations

Locations

Site City State Country Postal Code
1 UCAM San Antonio Catholic University of Murcia Murcia Spain 30107

Sponsors and Collaborators

  • Universidad Católica San Antonio de Murcia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Desirée Victoria Montesinos, Principal Investigator, Universidad Católica San Antonio de Murcia
ClinicalTrials.gov Identifier:
NCT05758363
Other Study ID Numbers:
  • CE012309
First Posted:
Mar 7, 2023
Last Update Posted:
Mar 10, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 10, 2023